Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA …
Biotech News | BioPharma Dive
5 days ago · The latest biotech news for biopharmaceutical professionals
Pharma News | BioPharma Dive
Nov 7, 2025 · The latest pharma news for biotech and biopharmaceutical professionals
Clinical Trial News | BioPharma Dive
5 days ago · The latest clinical trial news for biotech and biopharmaceutical professionals
Deep Dive - BioPharma Dive
Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net …
10 clinical trials to watch the rest of 2025 | BioPharma Dive
Jan 2, 2025 · 10 clinical trials to watch the rest of 2025 Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology …
The biopharma industry outlook on 2025: Uncertainty and change
Jan 24, 2025 · The biopharma industry outlook on 2025: Uncertainty and change The Trump administration is bringing new instability to a sector already grappling with a shaky market as …
Biotech IPOs are the industry’s lifeblood. Track how ... - BioPharma …
Nov 6, 2025 · Including Evommune’s IPO Wednesday, only 10 biotechs have gone public in 2025, less than half the nearly two dozen that had priced offerings by this time last year.
What will 2025 hold for biopharma? | BioPharma Dive
Jan 21, 2025 · Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – …
Biotech's M&A outlook is uncertain. Track the deals ... - BioPharma …
5 days ago · Pfizer’s winning bid for Metsera brought the deal’s total value to $10 billion, tying it for the third-largest biopharmaceutical company acquisition this year.